Oncology

Rucaparib showed longer progression-free survival, chemotherapy-free interval, and time to first subsequent treatment in advanced ovarian cancer patients, according to updated results from the ATHENA-MONO study.

ESGO 2025 study reveals overestimation of preoperative tumour size in stage IB2 cervical cancer, influencing adjuvant therapy decisions.

At the 2025 ESGO Annual Meeting, researchers unveiled two new diagnostic indices “Vienna Index” and “Top Vienna Index” which combine age with existing ovarian cancer biomarkers, significantly improving detection accuracy.

Study reveals a protein model to predict cardiomyopathy in childhood cancer survivors, enhancing early detection and intervention.

Aspirin was well-tolerated but did not significantly improve disease-free survival in high-risk colorectal cancer patients.

Personalised cancer vaccines show promise in preventing recurrence of high-risk kidney cancer, targeting key driver mutations.

U-Net neural network achieves 98.56% accuracy in brain tumour segmentation, promising advancements in neurological diagnostics and treatment planning.

Study reveals cancer survivors have lower dementia risk, suggesting potential shared biological mechanisms between cancer and neurodegeneration.